Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

about

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

Item

http://www.wikidata.org/entity/Q55110559

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

@en

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

@nl

type

Item

label

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

@en

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

@nl

prefLabel

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

@en

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

@nl

P1476

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

@en

P2093

Bing-Hsien Liu

http://www.w3.org/2001/XMLSchema#string

Che-Chuan Yang

http://www.w3.org/2001/XMLSchema#string

Herng-Er Horng

http://www.w3.org/2001/XMLSchema#string

Hsin-Hsien Chen

http://www.w3.org/2001/XMLSchema#string

Shieh-Yueh Yang

http://www.w3.org/2001/XMLSchema#string

P2860

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia

Second consensus statement on the diagnosis of multiple system atrophy

Alpha-synuclein and tau: teammates in neurodegeneration?

Parkinsonism: onset, progression and mortality

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990.

Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro.

P304

123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FNAGI.2018.00123

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chin-Hsien Lin

Ming-Jang Chiu

Jen-Jie Chieh

P577

2018-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29755341

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

biomarker

P932

5934438

http://www.w3.org/2001/XMLSchema#string